



Flu vaccines 2022 to 2023 season

<p>6 months to under 2 years</p> <p>In a clinical risk group</p> <p>QIVe (Quadrivalent influenza vaccine, egg-grown)⁽ⁱ⁾</p> <p>1^(v) 3</p>	<p>No contraindications to LAIV</p> <p>Quadrivalent LAIV (Live attenuated influenza vaccine, nasal spray suspension)</p> <p>2^(v)</p>	<p>If LAIV contraindicated or otherwise unsuitable⁽ⁱ⁾</p> <p>QIVc (Cell-based Quadrivalent Influenza Vaccine)</p> <p>4^(v)</p>	<p>18 years to less than 65 years in a clinical risk group; pregnant women</p> <p>QIVc (Cell-based Quadrivalent Influenza Vaccine)</p> <p>QIVr (Recombinant quadrivalent influenza vaccine) (18 years of age and above only)</p> <p>or QIVe (Quadrivalent influenza vaccine, egg grown) if QIVc or QIVr not available</p> <p>4 5 or 1 3</p>	<p>50 to 64 years not in a clinical risk group⁽ⁱⁱ⁾</p> <p>QIVe (Quadrivalent influenza vaccine, egg grown)</p> <p>or QIVc Cell-based Quadrivalent Influenza Vaccine⁽ⁱⁱⁱ⁾ or QIVr (Recombinant quadrivalent influenza vaccine)⁽ⁱⁱⁱ⁾</p> <p>1 3 or 4 5</p>	<p>65 years and over</p> <p>aQIV (Adjuvanted quadrivalent influenza vaccine)^(iv)</p> <p>QIVr (Recombinant quadrivalent influenza vaccine)</p> <p>or QIVc (Cell-based Quadrivalent Influenza Vaccine) if aQIV or QIVr not available</p> <p>6 5 or 4</p>
--	---	---	--	---	--

Quadrivalent Influenza Vaccine
Sanofi Pasteur

QIVe




1

licensed from 6 months of age

FluZex Tetra
AstraZeneca

LAIV



2

licensed from 2 years to less than 18 years of age

Influvac sub-unit Tetra ▼
Viatrix (formerly Mylan)

QIVe



3

licensed from 6 months of age

Cell-based Quadrivalent Influenza Vaccine ▼
Seqirus

QIVc



4

licensed from 2 years of age

Supertek ▼
Sanofi Pasteur

QIVr




5

licensed from 18 years of age

Adjuvanted Quadrivalent Influenza Vaccine ▼
Seqirus

aQIV



6

licensed from 65 years of age

Eligible groups

- aged 2 and 3 years on 31 August 2022
- school aged children (all Primary school aged children (Reception Year to Year 6) and eligible Secondary school aged children)
- those aged 6 months to under 50 years in clinical risk groups
- pregnant women
- 50 to 64 year olds

- all those aged 65 years and over
 - those in long-stay residential care homes
 - carers / in receipt of carer's allowance / or main carer of an older or disabled person
 - close contacts of immunocompromised individuals
 - frontline health and social care staff
- See Green Book Influenza Chapter 19 for full details on eligible groups**

Resources

- Annual flu programme**
www.gov.uk/government/collections/annual-flu-programme
- Green Book Influenza Chapter 19**
www.gov.uk/government/publications/influenza-the-green-book-chapter-19

(i) If the parent of an eligible child declines LAIV because of its porcine gelatine content (and they understand that it is more effective in the programme than the injected vaccines), they can request an alternative injectable vaccine. QIVc is available to order from Immuform for these children

(ii) Including those who turn 50 years of age by 31 March 2023. This cohort will become eligible starting from mid-October 2022 to allow prioritisation of at-risk groups

(iii) QIVc and QIVr should only be offered to the 50 to 64 years of age group (not in a clinical risk group) where it does not divert stock from clinical risk groups and those aged 65 years and over

(iv) Those who become 65 years of age before 31 March 2023 may be offered aQIV 'off-label'

(v) Vaccines for eligible children (under 18 years of age) are available to order from Immuform

(vi) For egg allergic children QIVc (Cell-based Quadrivalent Influenza Vaccine) can be given 'off-label'

Flu i mmunisation

Helping to protect people, every winter

UK Health Security Agency, gateway number: 20222110 02.20.2022

© Crown copyright 2022